Nurse Navigators and the Cancer Maze
The field of oncology nurse navigation continues to grow, responding to the complexity of cancer care and producing greater patient satisfaction.
Diagnosis & Disease Information
New Treatments for Metastatic Colorectal Cancer
Several new therapies for metastatic colorectal cancer have been developed and refined, changing the way the disease can be treated.
Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation
This CME activity from ASCO 2012 reviews the results of the ongoing PACE (Ponatinib Ph+ ALL and CML Evaluation) trial.
Dismiss a Problem Patient in 10 Safe Steps
Most clinicians have dealt with a dissatisfied or noncompliant patient. But how do you end the relationship without putting yourself at risk?
Coping With the Stress of Cancer Caregiving
This fact sheets details ways to manage stress, a common occurence among caregivers who struggle to meet competing demands.
Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer
This CME activity from ASCO 2012 reviews crizotinib in patients with ALK-positive non-small cell lung cancer.
Early Palliative Care Intervention Improves Satisfaction with Care, Prevents Decline in QOL in Patients with Metastatic Disease
This CME activity from ASCO 2012 describes the benefits of early palliative care in patients with metastatic cancer.
Carfilzomib, Lenalidomide, Low-Dose Dexamethasone Provides Rapid, Deep Responses in Patients with Newly Diagnosed Multiple Myeloma
This CME activity from ASCO 2012 reviews carfilzomib, lenalidomide, and low-dose dexamethasone in patients with newly diagnosed multiple myeloma.
Pomalidomide Active in Patients with Multiple Myeloma Refractory to Lenalidomide, Bortezomib—or Both—and in Transplant Failures
This CME activity reviews pomalidomide in combination with low-dose dexamethasone in patients with multiple myeloma refractory to lenalidomide, bortezomib, or both.
Interim Analysis Shows Abiraterone Acetate Significantly Improves Radiographic Progression-Free Survival in Chemo-Naïve Metastatic Castration-Resistant Prostate Cancer
This CME activity from ASCO 2012 reviews abiraterone acetate plus prednisone in patients with asymptomatic and mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer.
- Loading...
Loading...
Loading... 
Loading...